pharmaphorum

FEBRUARY 23, 2022

Interest in non-viral methods of delivering gene therapies has been growing in the face of current scrutiny of the safety of viral vectors like adeno-associated viruses (AAV), with a number of clinical programmes based on AAV under clinical holds imposed by the FDA.

Gene Therapy 103

Gene Therapy Gene Gene Sequencing Immune Response 103

Drug Discovery World

APRIL 17, 2023

Genetic sequencing To assess these alterations in groups of different ancestries, Walch and colleagues analysed targeted DNA sequencing data from 4,441 patients treated for colorectal cancer at MSK between 2014 and 2022. Tumours were sequenced using MSK-IMPACT, a gene sequencing panel that looks for mutations in up to 505 genes.

Genome 52

Genome Genomics Gene Sequencing Genome Project 52

Roots Analysis

FEBRUARY 23, 2022

Further, NGS library preparation kits offer several benefits, such as low requirement of starting material, generation of longer RNA / DNA sequences and production of superior quality nucleotide libraries, thereby, catering to existing unmet needs of the research domain. Next Generation Sequencing (NGS) Library Preparation Kits.

Genetics 52

Genetics DNA RNA Reagent 52

pharmaphorum

AUGUST 10, 2021

The decision was taken by the UUS regulator after a case of a rare blood cancer (myelodysplastic syndrome) was seen in a patient treated with Skysona that probably arose as a result of the lentiviral vector used to deliver the gene therapy.

Gene Therapy 135

Gene Therapy Gene Marketing Genetic Disease 135

Roots Analysis

OCTOBER 16, 2023

DNA cloning refers to the process of generating multiple copies of a particular DNA segment. DNA and Gene Cloning involves the isolation of a DNA sequence of any species ( often a gene ) and its insertion into a vector to enable growth without any alteration in the original DNA sequence.

DNA 40

DNA Gene Protein In-Vitro 40

Drug Discovery World

DECEMBER 13, 2022

Samples from individuals enrolled in multiple rare disease cohorts that have remained undiagnosed after short-read whole exome sequencing will be examined using HiFi WGS. . The study will also explore epigenetic variation using the ability of HiFi WGS to measure DNA methylation in every sequencing run. .

Genetics 52

Genetics Research Genome Genomics 52

pharmaphorum

FEBRUARY 22, 2021

That therapy uses an adeno-associated virus (AAV) as a vector rather than a lentivirus, a vector type that features in approved gene therapies such as Roche’s Luxturna and Novartis’ Zolgensma. million in Europe.

Gene Therapy 52

Gene Therapy Gene Gene Sequencing Gene Expression 52

pharmaphorum

OCTOBER 1, 2021

Shares in DNA sequencing specialist Oxford Nanopore rocketed after the company made its debut on the London Stock Exchange yesterday, rising nearly 50% to propel its valuation up towards the £5 billion ($6.7 billion) mark.

Marketing 52

Marketing Business Development Genome Genomics 52

Drug Discovery World

SEPTEMBER 28, 2023

This is the latest episode of the free DDW narrated podcast, “Overcoming different barriers in drug discovery”, which covers three articles written for Volume 23, Issue 3 – Summer 2022 of DDW.

Drugs 52

Drugs Development Gene Sequencing DNA 52

pharmaphorum

AUGUST 21, 2020

Cambridge, UK-based Biofidelity has raised $12 million in first-round funding for its cancer diagnosis platform, which can detect mutations quicker than current approaches like gene sequencing. Both previously worked at Cambridge-based DNA sequencing specialist Base4 Innovation, where the technology was developed.

DNA 59

DNA Gene Sequencing Genetics FDA Approval 59

Drug Discovery World

MARCH 27, 2023

This approach supports a Five Safes framework – safe projects, safe people, safe data, safe settings, and safe outputs. Room for growth While TREs offer enormous potential, they are not yet a panacea for the complexities of DNA analysis. TREs are effectively still in their infancy and lack universal standards and guidelines.

Genome 52

Genome Genomics Research Scientist 52

Pharmaceutical Technology

MAY 26, 2023

Enzymatic DNA production company Touchlight have augmented its DNA production capabilities with a newly announced expansion to its London facilities. Tripling its production capacity, Touchlight can now manufacture 8kg plasmid DNA, a key component for mRNA gene therapies and vaccines.

DNA 130

DNA Manufacturing Gene Therapy Gene 130